CLABSI: NHSN Surveillance Definition, LCBI Criteria, and Reporting

CLABSI (central line-associated bloodstream infection) is a National Healthcare Safety Network (NHSN) surveillance category, not a clinical diagnosis. NHSN defines it through a structured, retrospective algorithm: an eligible central line must have been present on or before the date a laboratory-confirmed bloodstream infection (LCBI) is identified, and that BSI must not be attributable to an infection at another body site. Whether a specific patient’s bloodstream infection meets that definition is a judgment call built from several linked rules — device eligibility, organism classification, symptom timing, and secondary-source attribution — not a single lab value. This guide works through that adjudication using the criteria published in the CDC NHSN Patient Safety Component Manual, Device-associated Module, Chapter 4 (Bloodstream Infection Event), January 2024 edition, the most recent edition available for direct verification. NHSN revises this manual annually, typically each January; confirm the current-year manual before using any of this for official reporting.

Surveillance CLABSI Is Not the Same Thing as a Clinical Line Infection

This is the distinction that drives the most confusion in the field, and it has real consequences: CLABSI rates feed CMS Hospital-Acquired Condition (HAC) Reduction Program penalties and public reporting, so a hospital’s reportable CLABSI count is not simply “however many line infections the clinical team treated.”

• A patient can be clinically treated for a catheter-related bloodstream infection (CRBSI) — the clinical/diagnostic concept, which typically involves quantitative or differential-time-to-positivity blood cultures drawn from the catheter and a peripheral vein — without that episode ever meeting the NHSN LCBI/CLABSI surveillance criteria (for example, if the required organism, symptom, or timing elements weren’t documented in the way NHSN requires).
• Conversely, a patient can meet the NHSN CLABSI surveillance definition — an eligible organism identified in blood, with an eligible central line present, not attributable to another site — without a clinician ever having diagnosed or treated the episode as a “line infection” specifically.
• CRBSI and CLABSI are measuring different things for different purposes: CRBSI is a bedside diagnostic concept aimed at guiding treatment of an individual patient; CLABSI is a standardized, retrospectively-applied surveillance definition aimed at producing comparable infection rates across facilities. StatPearls’ overview of CLABSI (NBK430891) draws this same distinction between the clinical and surveillance concepts.

Because of this gap, an infection preventionist adjudicating a case is applying the NHSN algorithm as written — not asking “did this patient clinically have a line infection.”

Step 1: Is There an Eligible Central Line?

NHSN defines a central line as an intravascular catheter that terminates at or close to the heart or in one of a defined list of great vessels — the aorta, pulmonary artery, superior vena cava, inferior vena cava, brachiocephalic veins, internal jugular veins, subclavian veins, external iliac veins, common iliac veins, or femoral veins (and, in neonates, the umbilical artery/vein) — AND is used for infusion, withdrawal of blood, or hemodynamic monitoring. Neither the device type nor the insertion site determines central-line status; function and tip location do. Types recognized for NHSN reporting are permanent central lines (tunneled catheters, including tunneled dialysis catheters, and implanted ports), temporary (non-tunneled, non-implanted) catheters, and umbilical catheters, which are always considered central lines.

Several devices that clinicians often think of as “central” are explicitly excluded from CLABSI surveillance: arterial catheters (unless placed in the pulmonary artery, aorta, or umbilical artery), arteriovenous fistulas and grafts, transthoracic intra-cardiac (atrial) catheters, ECMO cannulae, hemodialysis reliable outflow (HERO) catheters, intra-aortic balloon pump devices, peripheral IVs and midlines, and ventricular assist devices.

A line becomes an eligible central line once it has been in place for more than two consecutive calendar days — that is, on or after central-line day 3, counting from first access in an inpatient location during the current admission. It remains eligible until the day after removal from the body or discharge, whichever comes first. This >2-day threshold is the same device-day logic used across NHSN’s device-associated modules (compare the catheter-day rule for CAUTI).

Step 2: Does the Case Meet an LCBI Criterion?

A laboratory-confirmed bloodstream infection is met by satisfying one of three criteria, and the correct one depends on the organism and, for LCBI 3, patient age:

• LCBI 1 — A recognized bacterial or fungal pathogen (not on NHSN’s common commensal list) is identified from one or more blood specimens by culture, or identified to genus/species level by a non-culture-based microbiologic testing (NCT) method such as T2 Magnetic Resonance or next-generation sequencing (with rules governing which result — culture or NCT — takes precedence when both are done close together), AND the organism is not related to an infection at another site.
• LCBI 2 (any age) — At least one sign or symptom of fever (>38.0°C), chills, or hypotension, AND the organism is not related to an infection at another site, AND the same NHSN common commensal is identified by culture from two or more separate blood specimens. All elements must fall within the 7-day infection window period (IWP): the collection date of the positive specimen plus three calendar days before and three after.
• LCBI 3 (patients ≤1 year of age) — The same two-matching-commensal-specimen structure as LCBI 2, but with sign/symptom options specific to infants: fever, hypothermia (<36.0°C), apnea, or bradycardia, within the same 7-day IWP.

The date of event (DOE) for LCBI 1 is always the collection date of the first positive blood specimen. For LCBI 2/3, the DOE is the date the first qualifying element — sign, symptom, or specimen — occurs within the IWP, which is not always the same date as the positive culture.

Step 3: Check for MBI-LCBI

Once an LCBI criterion is met, NHSN requires checking whether the case also meets the corresponding Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infection (MBI-LCBI) criteria — a subset used to flag BSIs in a specific, high-risk immunocompromised population where gut mucosal breakdown, not device management, is the presumed source organism route. MBI-LCBI requires the underlying LCBI criterion PLUS organisms limited to the NHSN MBI organism list (intestinal organisms for MBI-LCBI 1; only Viridans Group Streptococcus and/or Rothia spp. for MBI-LCBI 2/3) PLUS at least one of: an allogeneic hematopoietic stem cell transplant within the past year with documented Grade III/IV GI graft-versus-host disease or substantial diarrhea onset within 7 days before the specimen, OR neutropenia (ANC and/or WBC <500 cells/mm³ on at least two separate days within the same 7-day window used for the IWP).

MBI-LCBI status matters operationally: it is tracked as a distinct category within CLABSI surveillance, and several downstream public-reporting and pay-for-reporting programs treat MBI-LCBI differently from standard LCBI-driven CLABSI when calculating measures used for hospital comparison — confirm current treatment in the applicable program’s specifications (for example, CMS Hospital-Acquired Condition Reduction Program documentation) rather than assuming it is always excluded.

Step 4: Rule Out a Secondary BSI

Every LCBI criterion above includes the same clause: the organism identified in blood must not be related to an infection at another site. NHSN calls a BSI that is attributable elsewhere a secondary BSI — for example, a bloodstream infection seeded from a urinary tract infection, pneumonia, or surgical site infection that independently meets that site’s own NHSN criteria. A secondary BSI is not counted as a primary CLABSI even if an eligible central line was present. This determination uses the Secondary BSI Attribution Period (SBAP): the infection window period combined with the repeat infection timeframe, together spanning roughly 14–17 days depending on the date of event. Getting this step wrong in either direction is a common surveillance error — incorrectly attributing a genuinely device-related BSI to a coincidental urine culture undercounts CLABSI; failing to check for a qualifying secondary source overcounts it.

Putting It Together: What “CLABSI” Means as a Count

A case is a reportable CLABSI when: an eligible BSI organism is identified, an eligible central line was present on the LCBI date of event or the day before, and the BSI is not secondary to infection at another site. Facilities track central-line days as the denominator and CLABSI counts as the numerator to produce a rate, then compare observed CLABSIs to a risk-adjusted predicted number using the Standardized Infection Ratio (SIR) — see that entry for how the predicted count and confidence interval are actually calculated, and why a single ICU’s SIR can be statistically unstable with a small number of device-days.

Frequently Asked Questions

Is every catheter-related bloodstream infection a CLABSI?

No. A clinically diagnosed catheter-related bloodstream infection (CRBSI) and a surveillance-defined CLABSI are related but distinct concepts, and a case can satisfy one without the other. See the distinction above.

Does a peripheral IV or midline count toward CLABSI surveillance?

No. Peripheral IVs and midlines are explicitly excluded from NHSN’s central-line definition regardless of how long they’re in place.

How many days must a central line be in place before a bloodstream infection can count as a CLABSI?

The line must have been in place for more than two consecutive calendar days (eligible on or after central-line day 3), and be present on the LCBI date of event or the day before — or removed the day before that date of event.

What happens if the BSI is caused by a common commensal like coagulase-negative staphylococci?

Common commensals can still meet the LCBI 2 or LCBI 3 criteria, but only with matching organisms from two separate blood specimens plus a qualifying sign or symptom — a single positive culture with a common commensal alone does not meet LCBI.

Who decides whether a case meets the CLABSI definition?

In most US hospitals this adjudication is performed by an infection preventionist applying the NHSN criteria to the chart, not by the treating clinician’s diagnosis.

This guide summarizes the structure of the NHSN Chapter 4 (BSI/CLABSI) surveillance criteria as published in the January 2024 Patient Safety Component Manual for general orientation. It is not a substitute for the current-year NHSN manual, and it is not clinical guidance for individual patient management. For official reporting, always work from the exact current-year CDC NHSN manual chapter, organism list, and any program-specific reporting instructions (e.g., CMS HAC Reduction Program).

Related: see the Patient Safety & Infection Prevention hub, the CAUTI guide for the equivalent device-day and symptomatic-infection logic applied to urinary catheters, and the hemovigilance guide for how NHSN’s parallel transfusion-safety surveillance module works.